Medical Devices / Bioelectric Medicine / Surgical Equipment
Strategic Profile
Positioned as the pioneer in bioelectric medicine with proprietary nsPFA technology that creates a differentiated therapeutic approach. The company employs a utilization-based revenue model with the CellFX platform designed for multi-application expansion from dermatology into cardiac (atrial fibrillation) and other surgical specialties, creating multiple growth vectors.
Cyborg Score Rationale
Pulse Biosciences demonstrates strong commercial momentum with recent analyst price target increases (to $30 in Feb 2026) and recent ATM program establishment signaling confidence. However, the company remains unprofitable with negative EBITDA, and near-term profitability is not forecast within 3 years, creating execution risk despite innovative technology differentiation.
Top Insights
Proprietary nsPFA technology creates a defensible moat in emerging bioelectric medicine category with non-thermal cell clearing capability
Recent analyst upgrades (Oppenheimer price target raised to $30 from $22 in Feb 2026) and ATM program suggests growing institutional confidence despite unprofitability
Company cash-burning in pre-profitability stage with negative EBITDA of -$75.87M; capital efficiency and runway critical near-term risks
Named Competitors
Radiofrequency and Laser Ablation Devices — Traditional thermal ablation technology for surgical and dermatologic applications
Surgical Ablation Platforms — Established surgical device leader with cardiac ablation and surgical solutions
Dermatologic Treatment Devices — Laser and light-based dermatology device manufacturer
Recent Developments
(February 2026) Oppenheimer raised price target to $30 from $22
(February 2026) Established new $60 million ATM Program for capital raising